## Suppression of EJ cells tumorigenicity

In Vivo 7, 471-6

Citation Report

#	Article	IF	CITATIONS
1	Suppression of H-ras-mediated transformation in NIH3T3 cells by a ras ribozyme. Biochemical Pharmacology, 1994, 48, 1471-1475.	4.4	41
2	Ribozymes: biology, biochemistry, and implications for clinical medicine. Journal of Molecular Medicine, 1995, 73, 65-71.	3.9	28
3	Transgenic models and cancer treatment. Cancer Treatment Reviews, 1995, 21, 565-576.	7.7	1
4	Clinical applications of ribozymes. Lancet, The, 1995, 345, 1027-1031.	13.7	41
5	Use of an Anti-ras Ribozyme to Alter the Malignant Phenotype of a Human Bladder Cancer Cell Line. Journal of Urology, 1996, 156, 1186-1188.	0.4	18
6	Ribozymes: Structure, Function and Potential Therapy for Dominant Genetic Disorders. Annals of Medicine, 1996, 28, 499-510.	3.8	44
7	Suppression of the Malignant Phenotype of Melanoma Cells by Anti-Oncogene Ribozymes. Journal of Investigative Dermatology, 1996, 106, 275-280.	0.7	43
8	Tissue-Specific Expression of an Anti-ras Ribozyme Inhibits Proliferation of Human Malignant Melanoma Cells. Nucleic Acids Research, 1996, 24, 938-942.	14.5	54
9	Anti-oncogene Ribozymes for Cancer Gene Therapy. Advances in Pharmacology, 1997, 40, 207-257.	2.0	18
10	A Minimised Hammerhead Ribozyme with Activity against Interleukin-2 in Human Cells. Biochemical and Biophysical Research Communications, 1997, 231, 397-402.	2.1	16
11	Ribozyme-Mediated Cancer Gene Therapy. International Journal of Urology, 1997, 4, 329-337.	1.0	8
12	Oligonucleotides as modulators of cancer gene expression. , 1997, 74, 317-332.		30
13	Hammerhead Ribozyme Specifically Inhibits Mutant K-ras mRNA of Human Pancreatic Cancer Cells. Biochemical and Biophysical Research Communications, 1998, 253, 368-373.	2.1	24
14	Anti-tumorigenic effect of a K-ras ribozyme against human lung cancer cell line heterotransplants in nude mice. Gene Therapy, 2000, 7, 2041-2050.	4.5	48
15	Ribozyme as an Approach for Growth Suppression of Human Pancreatic Cancer. Molecular Biotechnology, 2000, 14, 59-72.	2.4	21
16	Chemically Modified Ribozyme to V Gene Inhibits Anti-DNA Production and the Formation of Immune Deposits Caused by Lupus Lymphocytes. Journal of Immunology, 2000, 165, 5900-5905.	0.8	8
17	EGF Family Receptors and Their Ligands in Human Cancer. , 1998, , 113-165.		13
18	Use of an Anti-ras Ribozyme to Alter the Malignant Phenotype of a Human Bladder Cancer Cell Line. Journal of Urology, 1996, , 1186-1188.	0.4	2

#	Article	IF	CITATIONS
19	Parvovirus Vectors for the Gene Therapy of Cancer. , 2002, , 53-79.		0
20	Ribozymes in Cancer Gene Therapy. , 2002, , 95-108.		0
21	A Case for ras Targeted Agents as Antineoplastics. , 1997, , 395-415.		2
22	New approaches for cancer treatment: antitumor drugs based on gene-targeted nucleic acids. Acta Naturae, 2009, 1, 44-60.	1.7	3